REGULATORY CONSIDERATIONS ON ADDITIONAL RISK MINIMIZATION MEASURES IN EUROPE

Additional Risk Minimization Measures (aRMMs) are crucial in the European regulatory framework to enhance pharmaceutical safety when routine risk management strategies are inadequate. These measures are implemented when a medicinal product poses risks such as severe adverse reactions, misuse, or teratogenicity, which cannot be adequately controlled through standard pharmacovigilance processes. In Europe, the European Medicines Agency (EMA) plays a central role in overseeing the development, implementation, and monitoring of aRMMs, ensuring that these strategies are both effective and compliant with EU pharmacovigilance legislation. While prior reviews have examined pharmacovigilance strategies, gaps remain in assessing the real-world implementation challenges of aRMMs, their regulatory effectiveness, and their impact on healthcare systems and patient access. Current regulatory reviews have not comprehensively addressed the evolving complexities of compliance with EU pharmacovigilance legislation, particularly in balancing stringent safety requirements with practical drug accessibility. This review bridges these gaps by analyzing the regulatory framework governing aRMMs, including legal mandates for risk management plans (RMPs), post-marketing surveillance strategies, and ongoing safety monitoring through registries and studies. By offering a novel perspective on optimizing aRMM implementation and identifying areas for regulatory enhancement, this review contributes to a more comprehensive understanding of risk minimization strategies. It stresses the necessity for continuous evaluation and adaptation to ensure that pharmaceutical benefits outweigh risks while maintaining accessibility.